Patient was admitted in hospital by 30aug 2025.. Aml was diagnosed, co

IMG-20260721-WA0001.jpg

IMG-20260716-WA0005.jpg

Patient was admitted in hospital by 30aug 2025.. Aml was diagnosed, confirmed in 3 sept, treatment started with azacytidine , patient went to ICU as since admitted was in Oxygen only, pneumonia was not getting cured, later after 4 days in ICU shifted back to ward started venetoclax, got cardiac arrest again to ICU by 15th spet out of ICU but was unable to walk due to too much weakness n swelling in legs due to hypoalbuminea.. gradually got better in October 2nd chemo went smoothly november too.. in December by 31st BMT transplant was done, full match, got discharged by 1st Feb.. than in March got the viral infection treated with Ime-cila... Now the patient is fine doing well this is the latest report of the patient, but just one thing why there's need of gonadotropin here, as patient is already aged, so we don't need virility anyhow...

Reading File

analyse_media

Looking at this case, there's a lot packed into one story - from AML diagnosis through ICU crises to BMT and now maintenance therapy with a puzzling HCG order. Let me map out what this actually covers before going deep on any one piece.

Topic breakdown:

AML diagnosis & induction (Aza+Ven) - hypomethylating agent + BCL-2 inhibitor combo, why this regimen for this patient
ICU course #1 - refractory pneumonia on oxygen, respiratory failure while on active leukemia treatment
ICU course #2 (cardiac arrest) - re-arrest after venetoclax start, tumor lysis / cytopenia / sepsis risk
Hypoalbuminemia + critical illness weakness - why prolonged ICU stay caused leg swelling and inability to walk (critical illness myopathy/neuropathy, capillary leak)
Maintenance chemo phase (Oct-Nov) - what "going smoothly" means for AML monitoring
Allogeneic BMT (full match, Dec 31) - transplant basics, conditioning, engraftment, discharge criteria
Post-BMT viral infection (March) - likely CMV or similar, treated with an antiviral ("Ime-cila" likely a mis-transcription)
Current maintenance prescription, including the HCG/gonadotropin question - Inj Hucog (UHHCG), Arachitol (vitamin D3), Wysolone taper, Septran-DS prophylaxis, and why hCG appears here despite the patient's age

Quick overview: this is a fairly classic (if rocky) trajectory for an older AML patient - venetoclax-based induction, infection and cardiac complications typical of the neutropenic/critically-ill phase, then a slow recovery through maintenance chemo into a full-match allogeneic BMT, with routine post-transplant antimicrobial/viral prophylaxis now. The one item that looks out of place to a layperson - Inj Hucog (human chorionic gonadotropin) - is in fact not being given here for fertility or virility at all; in this setting it's almost always used for a completely different, non-reproductive reason tied to the muscle wasting/hypogonadism that can follow steroids, chemo, and prolonged critical illness. That's clearly the piece you actually want explained in depth.

Asking for Preferences

Which part do you want me to go deep on? (I suspect it's #8 - the HCG/gonadotropin question - but confirming)

Topic breakdown:

AML diagnosis & induction (Aza+Ven) - hypomethylating agent + BCL-2 inhibitor combo, why this regimen for this patient
ICU course #1 - refractory pneumonia on oxygen, respiratory failure while on active leukemia treatment
ICU course #2 (cardiac arrest) - re-arrest after venetoclax start, tumor lysis / cytopenia / sepsis risk
Hypoalbuminemia + critical illness weakness - why prolonged ICU stay caused leg swelling and inability to walk (critical illness myopathy/neuropathy, capillary leak)
Maintenance chemo phase (Oct-Nov) - what "going smoothly" means for AML monitoring
Allogeneic BMT (full match, Dec 31) - transplant basics, conditioning, engraftment, discharge criteria
Post-BMT viral infection (March) - likely CMV or similar, treated with an antiviral ("Ime-cila" likely a mis-transcription)
Current maintenance prescription, including the HCG/gonadotropin question - Inj Hucog (UHHCG), Arachitol (vitamin D3), Wysolone taper, Septran-DS prophylaxis, and why hCG appears here despite the patient's age

Retry

Finding Sources

Searching PubMed

"human chorionic gonadotropin" AND hypogonadism

Searching the Web

HCG injection prescribed male hypogonadism steroid induced muscle weakness recovery not fertility

Good question, and the good news is the reasoning has nothing to do with "virility" or fertility at all.

What Inj Hucog (UHHCG) actually does

hCG (human chorionic gonadotropin) is not a fertility drug by mechanism, it's an LH-mimic. It binds the same receptor as luteinizing hormone on testicular Leydig cells and drives them to make testosterone - Guyton & Hall's Physiology describes this exact interstitial-cell-stimulating action. Fertility (sperm production) is a secondary use that additionally needs FSH; a single hCG injection given once weekly at 5000 IU, as ordered here, is a testosterone-support dose pattern, not a fertility-induction protocol (those regimens usually run 2-3x/week, often combined with FSH/hMG).

Why a testosterone boost matters here, at this age, in this patient

Look at what this man's body has been through since August:

Long ICU stays, sepsis/pneumonia, a cardiac arrest - classic drivers of critical illness catabolism and critical-illness myopathy
Severe hypoalbuminemia with leg swelling and inability to walk - protein/muscle wasting state
Steroids (Tab Wysolone/prednisolone) on the current prescription, tapering over weeks - steroids reliably suppress the hypothalamic-pituitary-gonadal axis and lower endogenous testosterone
Chemotherapy (Aza+Ven) and a full allogeneic BMT - both can suppress pituitary-gonadal signaling and testicular function

The combination of chronic illness, steroid exposure, and cytotoxic therapy commonly produces secondary (functional) hypogonadism - low testosterone not because the testes are permanently destroyed, but because upstream signaling is suppressed and the whole endocrine-metabolic state is catabolic. This is a well-recognized picture in medical literature: "Testosterone Replacement Therapy" sections in Family Medicine texts note that when the defect is pituitary/hypothalamic in origin, "gonadotropin replacement or human chorionic gonadotropin therapy is required" - Textbook of Family Medicine, 9th ed.

Low testosterone in this state directly worsens the exact problems he already had: muscle wasting, weakness, poor appetite, slow recovery of strength and mobility, and can impair wound/marrow recovery post-BMT. Restoring it with hCG is being used here as an anabolic/recovery adjunct, not for reproductive purposes. It pairs logically with the other supportive orders on the same sheet: Inj Arachitol (vitamin D3) for bone/muscle health, and Nutrico MC for nutritional repletion, this whole cluster reads as a "rebuild the body after prolonged critical illness and steroid/chemo exposure" bundle, with hCG covering the testosterone piece of that puzzle.

One caveat worth flagging to the treating team if it hasn't been checked: hCG only works if the testes themselves are still capable of responding (secondary/functional hypogonadism). If chemo or transplant conditioning caused primary testicular (Leydig cell) failure, hCG will be ineffective and direct testosterone replacement would be needed instead. Ideally this order should be, and likely was, guided by a baseline testosterone/LH/FSH level before starting - if that hasn't been checked, it's a reasonable thing to ask the oncology team about.

A quick note on evidence currency: hCG-for-hypogonadism literature is mostly older/case-based (mechanistically well established but not backed by large recent RCTs specific to post-transplant/critical-illness recovery), so this is standard endocrine reasoning applied to his situation rather than a guideline-driven protocol - reasonable to ask the transplant physician for the specific rationale (i.e., was a low testosterone level documented) if you want full confirmation.

What can exactly happen due to hypogonadism

Finding Sources

Searching PubMed

male hypogonadism clinical consequences

What Happens in Hypogonadism (Low Testosterone)

Testosterone acts on almost every organ system, so deficiency doesn't just cause sexual symptoms - it produces a broad clinical picture:

Musculoskeletal (most relevant to this patient)

Muscle wasting and weakness - testosterone is directly anabolic on skeletal muscle. Low levels cause loss of lean muscle mass and strength (Pfenninger and Fowler's Procedures for Primary Care, 3rd ed., notes men with testicular failure "suffer from... muscle weakness... and lassitude" as part of the core hypogonadism spectrum).
Osteoporosis and fracture risk - testosterone (via conversion to estradiol) maintains bone density. Untreated hypogonadism reliably leads to osteopenia/osteoporosis over time - Rockwood and Green's Fractures in Adults lists hypogonadism explicitly among diseases that raise fracture risk, and Textbook of Family Medicine states plainly: "If left untreated, men and women with hypogonadism develop osteoporosis."

Hematologic

Anemia - testosterone stimulates erythropoietin and marrow red cell production. Low testosterone is a recognized contributor to anemia, especially relevant here given this patient is post-AML/post-BMT and already at risk of cytopenias (Kaplan & Sadock's Psychiatry and Brenner and Rector's The Kidney both list anemia as a hypogonadism-related finding).

Metabolic/General

Fatigue, reduced stamina, lassitude, and generally slower recovery from illness
Fat redistribution and reduced insulin sensitivity with chronic deficiency
In Brenner and Rector's The Kidney, hypogonadism in chronically ill patients is tied to "decreased libido, erectile dysfunction... osteopenia and, to some extent, osteoporosis and anemia" - a cluster that overlaps heavily with what this patient is recovering from.

Psychological

Low mood, depression, and reduced motivation are part of the recognized hypogonadal syndrome, not just a side effect of being sick.

Sexual/reproductive (the part people usually think of first, but the smallest concern in this context)

Reduced libido, erectile dysfunction, infertility. In an older man not seeking fertility, this domain is clinically the least important, exactly your point.

Why this matters specifically for your patient

Every domain above except the reproductive one directly overlaps with the exact problems he's been fighting since August: muscle weakness and leg swelling from the ICU stay, hypoalbuminemia, general deconditioning, and now steroid taper plus ongoing maintenance chemo. Correcting testosterone via hCG isn't about virility, it's aimed at the muscle-strength, bone, and anemia axis of hypogonadism, which is exactly what a frail post-critical-illness, post-transplant patient needs support with.

One more relevant data point: a 2024 systematic review specifically on anticancer drug-related hypogonadism (Massa et al., The Oncologist, PMID: 38518107) found this is common in men on active cancer treatment and contributes meaningfully to fatigue and reduced quality of life during treatment, reinforcing that checking for and correcting it in a patient like this is standard supportive oncology practice, not an incidental or unnecessary order.

Have you seen the reports.. birubin has increased, basophil n monocytes too, in the reports 45 days before these were normal

Reading File

Browsing Directory

~/attachments/a35447ab-ef31-49c1-aab1-ed2b65a8d5f6

Browsing Directory

~/attachments

I don't actually have access to any lab report right now, I should flag that clearly:

No file was attached to this message.
The images/PDF you shared earlier in this chat are no longer available in my sandbox (the session attachment folder is now empty), so I can't re-check the actual bilirubin, basophil, or monocyte numbers from before.

Please re-upload the report(s) - ideally both the current one and the one from ~45 days ago - so I can look at the actual values, trend, and any accompanying LFT/CBC panel rather than guess.

That said, since this is time-sensitive and clinically relevant, here's the framework I'll apply once I see the numbers - context matters a lot in a post-allogeneic-BMT AML patient on Aza+Ven maintenance who also had a viral infection in March:

Finding Sources

Searching PubMed

hepatic graft versus host disease bilirubin monocytosis allogeneic transplant

Since I don't have the actual report values to confirm trends, treat what follows as a framework to interpret it once you re-upload the file, not a diagnosis.

Bilirubin rising

In a post-allogeneic BMT patient, a new bilirubin rise is a genuine chase-it-down finding, not something to sit on. The leading possibilities, per Harrison's Principles of Internal Medicine and Sleisenger & Fordtran's GI/Liver Disease, are:

Hepatic graft-versus-host disease (GVHD) - classic cause of new jaundice after allo-BMT, often cholestatic pattern (bilirubin + alkaline phosphatase rise more than transaminases), can involve bile duct injury/ductopenia if it becomes chronic.
Sinusoidal obstruction syndrome / veno-occlusive disease - another BMT-specific cause of jaundice, usually earlier post-transplant but can recur.
Drug-induced hepatotoxicity - Aza+Ven, azole/antiviral drugs, or Septran-DS can all stress the liver.
Sepsis/infection-related cholestasis - "sepsis and GVHD" are explicitly named together as the two big differentials for unexplained bilirubin rise post-transplant.
Hemolysis - less likely but worth a quick check (haptoglobin, LDH, reticulocyte count) since it's a simple thing to rule in/out.

Basophils and monocytes rising together

This combination deserves attention because of what it can represent in someone with an AML history:

Reactive/benign causes: post-BMT marrow recovery and engraftment often shows monocyte predominance as an early recovery signal; basophilia can also be a nonspecific reactive response to inflammation, allergic/drug reactions, or infection recovery.
Chronic GVHD marker: a 2024 study (Marrero-Cepeda et al., Bone Marrow Transplantation, PMID: 38909123) found monocytosis to be a prognostic factor specifically for chronic GVHD, worth knowing given bilirubin is also up, this raises the GVHD hypothesis higher on the list rather than being two unrelated findings.
Disease relapse concern: this is the one that needs to be actively excluded, not assumed. Basophilia is classically linked with myeloid neoplasms (Tietz Textbook of Laboratory Medicine, Henry's Clinical Diagnosis and Management), and a rising monocyte fraction in someone with a treated AML is exactly the pattern hematologists watch for as an early relapse or clonal evolution signal (including AML with monocytic differentiation). This is the reason this trio of changes, appearing together 45 days apart, should go straight to his hematology/BMT team rather than be interpreted at home.

Bottom line

Three real possibilities sit side by side here: reactive/recovery changes (benign), hepatic/chronic GVHD (needs treatment adjustment), or early relapse signal (needs urgent marrow workup). The only way to tell them apart is the actual numbers plus context, absolute basophil/monocyte counts, bilirubin fractionation (direct vs indirect), ALT/AST/ALP trend, and whether there's any new skin rash, diarrhea, or GI symptoms (GVHD) versus systemic symptoms.

Please share the actual report (upload again) so I can look at the real values, and I'd also flag this finding to his treating hematologist/BMT physician directly given the current follow-up date on his prescription (08/08/2026) may be too far out if this trend is real and progressing. That call shouldn't wait for a scheduled visit.

I don't have prior once

Running Command

cd /tmp/workspace/attachments/a35447ab-ef31-49c1-aab1-ed2b65a8d5f6 && python3 -c " import pdfplumber with pdfplumber.open('2026_08_24_HC_7070032.pdf') as pdf: print('Pages:', len(pdf.pages)) for i, page in enumerate(pdf.pages): print(f'--- Page {i+1} ---') text = page.extract_text() print(text) print() tables = page.extract_tables() for t in tables: for row in t: print(row) "

Finding Sources

Good, I have your actual report now (24/08/2026, Yashoda Hospitals, Dr. Ganesh S. Jaishetwar). Since you don't have the prior report, I can't confirm the "45 days ago vs now" trend directly, but I can tell you exactly where each value stands today, and it's more reassuring than it sounded.

Bilirubin - actually NORMAL

Total Bilirubin: 0.62 mg/dL (ref 0.2-1.3) - normal
Conjugated/Bc (direct enzymatic method): 0.00 (ref 0-0.3) - normal
Unconjugated/Bu: 0.17 (ref 0-1.1) - normal
"Direct Bilirubin" (calculated field): 0.44 (ref 0-0.3) - mildly above range, but this is a calculated sub-fraction, and the report's own footnote explains why Bc+Bu don't always match the calculated "direct" or total figure (delta-bilirubin bound to albumin skews the math). With total bilirubin, ALP (89, ref 38-126), and GGT (38, ref 15-73) all normal, there is no biochemical pattern of cholestasis or hepatic GVHD today. SGPT is only trivially high (55 vs ref 0-50) and SGOT sits right at the top of normal (58 vs ref 17-59). This is a mild, non-alarming liver picture, not the "increased bilirubin" red flag it sounded like.

Monocytes and basophils - this is the key correction

Both were reported as elevated percentages, but percentages in a differential count always add up to 100%. When one line (lymphocytes, at 39.6%, near the top of normal) sits high, the others get pushed up proportionally even if the actual cell numbers haven't changed. What matters clinically is the absolute count:

Cell	% (looks high)	Absolute count	Reference	Verdict
Monocytes	15.8% (ref 2-10%)	920/cu mm	200-1000	Normal
Basophils	1.2% (ref 0-1%)	70/cu mm	20-100	Normal

Both absolute counts are comfortably inside normal range. On top of that, the pathologist who personally reviewed the peripheral smear signed off: "WBC Normal in count and distribution." That manual review is the most trustworthy line on the whole report, and it's reassuring. There's no morphologic evidence here pointing toward relapse, CMML-type transformation, or anything concerning, this looks like a relative shift in the differential math, not a true rise in these cell lines.

Other things worth flagging (minor, not urgent)

Mild anemia: Hb 13.2 (ref 13-17, low end), RBC count 3.86 million (ref 4.5-5.5, low), PCV 38% (ref 40-50, low), with MCV/MCH on the high side, mildly macrocytic pattern. This is common with azacitidine (a hypomethylating agent known to cause macrocytosis) and with post-transplant marrow recovery, generally not worrying on its own.
Sodium 134 (ref 137-145) - mildly low, but the lab itself flags that IV-line draws can artificially skew electrolytes, worth a repeat on a clean venipuncture if not already done.
Urine: trace protein, a few RBCs/pus cells, few bacteria - nonspecific, could just reflect a slightly concentrated or contaminated sample; not diagnostic of infection by itself.
Albumin is back to 3.90 g/dL (normal, ref 3.5-5) - a genuinely good sign given how low it was during his ICU stay with leg swelling.

Bottom line: based on this single report, nothing here looks like GVHD, hepatotoxicity, or relapse. The "increases" you were seeing were almost certainly the percentage columns, not the absolute counts, and the absolute counts plus the pathologist's smear review are both normal. Still worth mentioning to Dr. Jaishetwar at the 08/08/2026-scheduled follow-up (or sooner if he develops fever, jaundice, rash, or new symptoms), but this is not an urgent red flag as it initially seemed.

This is a shared conversation. Sign in to Orris to start your own chat.